Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: obatoclax mesylate, obatoclax | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 376 | 0.91 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 12154
Sealed predictions
- BCL2A1 in dopamine neurons, braak+0.42 (p 0.258) → -0.26 (p 0.500)receipt 12162
Swarm cases
receipt 12162: BCL2A1 in dopamine neurons, braak
- power
- full sample +0.29 (p 0.250, n 18), 95% CI -0.21 to +0.66. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.29 (p 0.250, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.31 (p 0.204, n 18). could be the mix.
- skeptic
- leave-one-out range +0.18 to +0.36, sign flips 0; without severely affected donors +0.29 (p 0.250, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for BCL2A1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts